On July 27, 2006, the European Union (EU) followed America's lead and gave conditional approve to Pfizer's new drug Sutent (sunitinib, formerly known as SU11248) as a treatment for advanced kidney cancer. The drug is also being used as a treatment for a rare type of cancer known as gastrointestinal stromal tumor (GIST).But how effective is it?Sutent is one of the latest crop of 'targeted' therapies for various kinds of cancer. It is given as a 50 milligram (mg) pill once per day. Technically speaking, it contains small-molecule inhibitors of the tyrosine kinase portion of the VEGF and PDGF receptors. ...